)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Bausch Health
Bausch Health (BHC) investor relations material
Bausch Health 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic priorities and business overview
Focus on profitable growth, capital structure improvement, and investment in people, products, and processes.
Operates as a ~$5B global pharmaceutical and devices company in ~50 countries, with 12 manufacturing sites, 600+ products, and over 7,000 employees.
Four business segments: Salix (GI/hepatology), International (branded generics), Solta Medical (aesthetics), and Diversified (neuroscience, dermatology, dentistry).
Built a diversified portfolio over 65 years through acquisitions and organic growth, including recent additions like Larsucosterol and the announced spin-off of Bausch + Lomb.
Management team has deep expertise in pharmaceuticals and medical devices, supporting continued growth and innovation.
Financial performance and guidance
Reported 2024 revenue of $4.83B, adjusted EBITDA of $2.55B, and adjusted cash flow from operations of $1.31B (all non-GAAP, ex-Bausch + Lomb).
Each business segment delivers meaningful value: Salix ($2.33B revenue, $1.60B profit), International ($1.11B, $376M), Diversified ($950M, $626M), Solta ($440M, $213M).
Demonstrated consistent, profitable growth with YoY revenue and adjusted EBITDA increases across 2024 and into 2025.
2025 guidance reiterates ~4% revenue growth and ~7% adjusted EBITDA growth, with revenue expected between $5.0B–$5.1B and adjusted EBITDA of $2.7B–$2.75B.
Non-GAAP measures are used for internal evaluation and investor communication, with detailed reconciliations provided.
Segment performance and growth drivers
Salix leads in GI/hepatology, with 12% revenue growth in Q3 2025 and strong Xifaxan script growth; Xifaxan is the only FDA-approved medicine to reduce OHE recurrence risk.
Solta Medical is a global leader in medical aesthetics, especially in APAC, with revenue growing from $99M in 2014 to $519M in 2024 and Thermage® surpassing 5 million treatments.
International segment holds top market positions in Central Europe, Mexico, Canada, and across EMEA, LATAM, and Canada, with new launches in cardiometabolic and probiotic franchises.
Neuroscience is the second largest U.S. contributor, reaching 12,000 psychiatrists/PCPs and representing 80% of the neuroscience business, with 10 consecutive quarters of profitable growth.
All segments maintain attractive profit margins and operate in large, growing markets.
Detail capital structure strategy post-Xifaxan LOE.
Red Sea program's market potential vs. Xifaxan?
Solta's data generation strategy for growth.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Bausch Health earnings date
Q4 202518 Feb, 2026
Bausch Health
Next Bausch Health earnings date
Q4 202518 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Bausch Health Companies Inc. develops, manufactures, and markets pharmaceutical, medical device, and over-the-counter products. Its offerings span therapeutic areas such as dermatology, eye health, and gastroenterology. The company is headquartered in Laval, Canada, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage